EICHORCondition: Nasopharyngeal Carcinoma · Immune Checkpoint Inhibitor · Radiotherapy · Sponsor: Sun Yat-sen University
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.
This description comes directly from the study's public registry record.
Chong Zhao, MD, PhD · 02087342638 · zhaochong@sysucc.org.cn
Jingjing Miao, MD · +8613631355201 · miaojj@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Cancer Center, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | Not Yet Recruiting |
| Jiangxi Cancer Hospital | Nanchang, Jiangxi, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05941741